Navigation Links
NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
Date:5/12/2009

Hamburg, Germany and Copenhagen, Denmark, May 12th, 2009 / b3c newswire / – Richter-Helm BioLogics GmbH & Co. KG announces today a technological breakthrough in the field of purification of antibody fragments from an E. coli expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.

Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture.  The simplified process is less likely to cause processing problems.  The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation.  The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture.

Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.

Rhobust® has improved Richter-Helm’s offering to customers operating with microbial derived products, providing a superior downstream process for clinical manufacturing. Richter-Helm embraced this technology under tight timelines and cost pressures and has been rewarded with a superior downstream offering in the CMO market.

The Rhobust® universal processing platform from Upfront Chromatography enables customers to efficiently capture and purify monoclonal antibodies, therapeutic proteins and other biomolecules directly from blood plasma or bioreactors, without the need for prior filtration.  

Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.


For further information please contact:

Richter-Helm:
Dr. Kai Pohlmeyer
Head of Business Development
Phone: +49-40-2375-2430  
Mail: k.pohlmeyer@richter-helm-biotec.eu

--> Meet us at Bio2009 Booth number 5222


Upfront :
Rob Noel
Global Manager
Business Development
Phone: +44 7970 930895,
Mail: robnoel@upfront-dk.com

Natalya Clark
Marketing/PR Manager
Phone:.+4539174337
Mail: nac@upfront-dk.com

--> Meet us at Bio2009 Booth number 5123 BioProcess Zone 


'/>"/>
b3c newswire

Related biology news :

1. Novel antibody prevents infection by hepatitis C virus
2. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
3. Antibody key to treating variant CJD, scientists find
4. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
5. ETH Zurich researchers develop antibody test
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Yale chemist receives NIH Young Investigator Award for antibody targeting
8. Reversing cognitive deficits: Injectable antibody may attack source of problem
9. Fossil fragments reveal 500-million-year-old monster predator
10. The song doesnt remain the same in fragmented bird populations
11. EMBL scientists develop first fully automated pipeline for multiprotein complex production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: